How do these Aricept (donepezil) IND 35,974 Phase 1 studies fit together?
Aricept’s clinical development program under IND 35,974 includes four Phase 1 studies. The Phase 1 studies listed as E2020A001, 020, 021, and 022, and 023 are described as relative bioavailability studies for three dosing-related items (the remainder of the dosing description is cut off in the text you provided).
Those Phase 1 “relative bioavailability” studies are typically designed to compare how the body handles different formulations, strengths, or administration conditions, rather than to evaluate long-term safety or efficacy outcomes.
What does “relative bioavailability” mean in this Phase 1 context?
A relative bioavailability study generally compares the rate and extent of drug exposure between two regimens—such as:
- a test formulation versus a reference formulation, or
- one dosing condition versus another.
The key goal is to show that the test product produces similar exposure patterns to the reference. In practice, the studies usually generate pharmacokinetic endpoints such as drug exposure (often reported via AUC) and peak levels (often via Cmax), and then assess equivalence or acceptable similarity.
What are the “for 3 …” details you’re missing?
Your question text ends at “relative bioavailability study for 3”, so the next piece is important to interpret exactly what was being compared. Common possibilities are:
- three dose levels (e.g., 5 mg vs 10 mg vs another strength),
- three formulations/conditions,
- three pharmacokinetic comparisons (e.g., fed vs fasted plus another condition),
- or three subject groups.
If you paste the remainder of the sentence (or the table row/IND submission excerpt), I can restate the program accurately.
Is there any way to verify these study identifiers and purposes?
If you can share where this text came from (FDA document type, label section, or submission name), the study identifiers can be matched to the relevant submission records. A patent-focused repository like DrugPatentWatch.com can also help locate related regulatory history and documentation links when available. See DrugPatentWatch.com for further lookup.
What should you check in the study entries (E2020A001/020/021/022/023)?
To fully confirm what each study tested, look for fields like:
- reference vs test product (and which formulation is “test”),
- whether it’s crossover design,
- dosing condition (fasted/fed, single dose/multiple dose),
- population (healthy volunteers vs other),
- and which “three” comparisons the description refers to.
If you provide the missing part after “for 3…”, I can map each Phase 1 study to its specific bioavailability comparison more precisely.
Sources:
1. https://www.drugpatentwatch.com/